You have free access to this content

8. Pancreatic and Biliary Cancer

  1. Janusz Jankowski MB ChB, MSc, MD, PhD, FRCP, FACG, AGAF2,3,4 and
  2. Ernest Hawk MD, MPH5
  1. Neil Bhardwaj and
  2. David M. Lloyd

Published Online: 15 NOV 2012

DOI: 10.1002/9781118423318.ch8

Handbook of Gastrointestinal Cancer

Handbook of Gastrointestinal Cancer

How to Cite

Bhardwaj, N. and Lloyd, D. M. (2012) Pancreatic and Biliary Cancer, in Handbook of Gastrointestinal Cancer (eds J. Jankowski and E. Hawk), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9781118423318.ch8

Editor Information

  1. 2

    Sir James Black Professor of Gastrointestinal Biology and Trials, Centre for Digestive Diseases, Barts and Th e London School of Medicine and Dentistry, London, UK

  2. 3

    Consultant Gastroenterologist, University Hospitals of Leicester, Leicester, UK

  3. 4

    James Black Senior Fellow, University of Oxford, Oxford, UK

  4. 5

    Vice President and Division Head, Division of Cancer Prevention & Population Sciences, Boone Pickens Distinguished Chair for Early Prevention of Cancer, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Author Information

  1. University Hospitals of Leicester, Leicester, UK

Publication History

  1. Published Online: 15 NOV 2012
  2. Published Print: 12 JUL 2012

ISBN Information

Print ISBN: 9780470656242

Online ISBN: 9781118423318



  • 1
    Jemal, A., Siegel, R., Xu, J., Ward, E. (2010) Cancer statistics, 2010. CA Cancer J Clin, 60(5), 277300.
  • 2
    Cancer Research UK. Pancreatic Cancer Statistics-Key Facts.; 2010; Available at:
  • 3
    Decker, G.A., Batheja, M.J., Collins, J.M. et al. Risk factors for pancreatic adenocarcinoma and prospects for screening. Gastroenterol Hepatol (NY), 6(4), 246254.
  • 4
    Gillen, S., Schuster, T., Meyer Zum Buschenfelde, C., Friess, H., Kleeff, J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med, 7(4), e1000267.
  • 5
    Yeo, C.J., Cameron, J.L., Lillemoe, K.D., Sitzmann, J.V., Hruban, R.H., Goodman, S.N. (1995) Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg, 221(6), 721731; discussion 31–33.
  • 6
    Li, D., Xie, K., Wolff, R., Abbruzzese, J.L. (2004) Pancreatic cancer. Lancet, 363(9414), 10491057.
  • 7
    Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., Perucho, M. (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell, 53(4), 549554.
  • 8
    Hruban, R.H., van Mansfeld, A.D., Offerhaus, G.J., van Weering, D.H., Allison, D.C., Goodman, S.N. (1993) K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol, 143(2), 545554.
  • 9
    Schutte, M., Hruban, R.H., Geradts, J., Maynard, R., Hilgers, W., Rabindran, S.K. (1997) Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Research, 57(15), 31263130.
  • 10
    Caldas, C., Hahn, S.A., da Costa, L.T., Redston, M.S., Schutte, M., Seymour, A. B. (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet, 8(1), 2732.
  • 11
    Weyrer, K., Feichtinger, H., Haun, M., Weiss, G., Ofner, D., Weger, A.R. (1996) p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas. Lab Invest, 74(1), 279289.
  • 12
    Ruggeri, B.A., Huang, L., Berger, D., Chang, H., Klein-Szanto, A.J., Goodrow, T. (1997) Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions. Cancer, 79(4), 700716.
  • 13
    Cubilla, A.L., Fitzgerald, P.J. (1976) Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Research, 36(7, Pt 2), 26902698.
  • 14
    Hruban, R.H., Adsay, N.V., Albores-Saavedra, J., Compton, C., Garrett, E.S., Goodman, S.N. (2001) Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol, 25(5), 579586.
  • 15
    Winter, J.M., Maitra, A., Yeo, C.J. (2006) Genetics and pathology of pancreatic cancer. HPB (Oxford), 8(5), 324336.
  • 16
    Luttges, J., Schlehe, B., Menke, M.A., Vogel, I., Henne-Bruns, D., Kloppel, G. (1999) The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium. Cancer, 85(8), 17031710.
  • 17
    Khan, I.Z., Conlon, K.C.P. (2009) Pancreatic adenocarcinoma. In: O.J. Garden (ed), Hepatobiliary and Pancreatic Surgery, pp. 283298. Elsevier.
  • 18
    Goggins, M., Hruban, R.H., Kern, S.E. (2000) BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol, 156(5), 17671771.
  • 19
    Wilentz, R.E., Iacobuzio-Donahue, C.A., Argani, P., McCarthy, D.M., Parsons, J.L., Yeo, C.J. (2000) Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Research, 60(7), 20022006.
  • 20
    Iodice, S., Gandini, S., Maisonneuve, P., Lowenfels, A.B. (2008) Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg, 393(4), 535545.
  • 21
    Hassan, M.M., Bondy, M.L., Wolff, R.A., Abbruzzese, J.L., Vauthey, J.N., Pisters, P.W. (2007) Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol, 102(12), 26962707.
    Direct Link:
  • 22
    Risch, H.A. (2003) Etiology of pancreatic cancer, with a hypothesis concerning the role of N-nitroso compounds and excess gastric acidity. J Natl Cancer Inst, 95(13), 948960.
  • 23
    Stevens, R.J., Roddam, A.W., Beral, V. (2007) Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis. Br J Cancer, 96(3), 507509.
  • 24
    Huxley, R., Ansary-Moghaddam, A., Berrington de Gonzalez, A., Barzi, F., Woodward, M. (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer, 92(11), 20762083.
  • 25
    Bansal, P., Sonnenberg, A. (1995) Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology, 109(1), 247251.
  • 26
    Malka, D., Hammel, P., Maire, F., Rufat, P., Madeira, I., Pessione, F. (2002) Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut, 51(6), 849852.
  • 27
    Tersmette, A.C., Petersen, G.M., Offerhaus, G.J., Falatko, F.C., Brune, K.A., Goggins, M. (2001) Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res, 7(3), 738744.
  • 28
    Giardiello, F.M., Brensinger, J.D., Tersmette, A.C., Goodman, S.N., Petersen, G.M., Booker, S.V. (2000) Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology, 119(6), 14471453.
  • 29
    Salovaara, R., Loukola, A., Kristo, P., Kaariainen, H., Ahtola, H., Eskelinen, M. (2000) Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol, 18(11), 21932200.
  • 30
    Lynch, H.T., Voorhees, G.J., Lanspa, S.J., McGreevy, P.S., Lynch, J.F. (1985) Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study. Br J Cancer, 52(2), 271273.
  • 31
    Rieder, H., Bartsch, D.K. (2004) Familial pancreatic cancer. Fam Cancer, 3(1), 6974.
  • 32
    Vasen, H.F., Gruis, N.A., Frants, R.R., van Der Velden, P.A., Hille, E.T., Bergman, W. (2000) Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer, 87(6), 809811.
  • 33
    Risch, H.A., McLaughlin, J.R., Cole, D.E., Rosen, B., Bradley, L., Fan, I. (2006) Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst, 98(23), 16941706.
  • 34
    van Asperen, C.J., Brohet, R.M., Meijers-Heijboer, E.J., Hoogerbrugge, N., Verhoef, S., Vasen, H.F. (2005) Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet, 42(9), 711719.
  • 35
    Lowenfels, A.B., Maisonneuve, P., DiMagno, E.P., Elitsur, Y., Gates, L.K. Jr., Perrault, J. (1997) Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst, 89(6), 442446.
  • 36
    Bakkevold, K.E., Arnesjo, B., Kambestad, B. (1992) Carcinoma of the pancreas and papilla of Vater: presenting symptoms, signs, and diagnosis related to stage and tumour site. A prospective multicentre trial in 472 patients. Norwegian Pancreatic Cancer Trial. Scand J Gastroenterol, 27(4), 317325.
  • 37
    Morris-Stiff, G., Teli, M., Jardine, N., Puntis, M.C. (2009) CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease. Hepatobiliary Pancreat Dis Int, 8(6), 620626.
  • 38
    Goonetilleke, K.S., Siriwardena, A.K. (2007) Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol, 33(3), 266270.
  • 39
    Nazli, O., Bozdag, A.D., Tansug, T., Kir, R., Kaymak, E. (2000) The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma. Hepatogastroenterology, 47(36), 17501752.
  • 40
    Safi, F., Schlosser, W., Falkenreck, S., Beger, H.G. (1996) CA 19-9 serum course and prognosis of pancreatic cancer. Int J Pancreatol, 20(3), 155161.
  • 41
    Marrelli, D., Caruso, S., Pedrazzani, C., Neri, A., Fernandes, E., Marini, M. (2009) CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg, 198(3), 333339.
  • 42
    Hidalgo, M. (2010) Pancreatic cancer. N Engl J Med, 362(17), 16051617.
  • 43
    Edge, S.B., Compton, C.C. (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 17(6), 14711474.
  • 44
    Tseng, J.F., Tamm, E.P., Lee, J.E., Pisters, P.W., Evans, D.B. (2006) Venous resection in pancreatic cancer surgery. Best Pract Res Clin Gastroenterol, 20(2), 349364.
  • 45
    Jimenez, R.E., Warshaw, A.L., Rattner, D.W., Willett, C.G., McGrath, D., Fernandez-del Castillo, C. (2000) Impact of laparoscopic staging in the treatment of pancreatic cancer. Arch Surg, 135(4), 409414; discussion 14–15.
  • 46
    Sewnath, M.E., Birjmohun, R.S., Rauws, E.A., Huibregtse, K., Obertop, H., Gouma, D.J. (2001) The effect of preoperative biliary drainage on postoperative complications after pancreaticoduodenectomy. J Am Coll Surg, 192(6), 726734.
  • 47
    Povoski, S.P., Karpeh, M.S. Jr., Conlon, K.C., Blumgart, L.H., Brennan, M.F. (1999) Association of preoperative biliary drainage with postoperative outcome following pancreaticoduodenectomy. Ann Surg, 230(2), 131142.
  • 48
    Whipple, A.O., Parsons, W.B., Mullins, C.R. (1935) Treatment of carcinoma of the ampulla of Vater. Ann Surg, 102(4), 763779.
  • 49
    McPhee, J.T., Hill, J.S., Whalen, G.F., Zayaruzny, M., Litwin, D.E., Sullivan, M.E. (2007) Perioperative mortality for pancreatectomy: a national perspective. Ann Surg, 246(2), 246253.
  • 50
    Berger, A.C., Garcia, M. Jr., Hoffman, J.P., Regine, W.F., Abrams, R.A., Safran, H. (2008) Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol, 26(36), 59185922.
  • 51
    Lieberman, M.D., Kilburn, H., Lindsey, M., Brennan, M.F. (1995) Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg, 222(5), 638645.
  • 52
    Dennison, A.R., Maddern, G.J. (2010) Pancreas. In: A.R. Dennison, G.J. Maddern (eds), Operative Solutions in Hepatobiliary and Pancreatic Surgery, pp. 187. Oxford University Press.
  • 53
    Connor, S. (2009) Non-adenocarcinoma of the pancreas. In: O.J. Garden (ed), Hepatobiliary and Pancreatic Surgery, pp. 299312. Elsevier.
  • 54
    Evans, D.B., Varadhachary, G.R., Crane, C.H., Sun, C.C., Lee, J.E., Pisters, P.W. (2008) Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol, 26(21), 34963502.
  • 55
    Varadhachary, G.R., Wolff, R.A., Crane, C.H., Sun, C.C., Lee, J.E., Pisters, P.W. (2008) Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol, 26(21), 34873495.
  • 56
    Kalser, M.H., Ellenberg, S.S. (1985) Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg, 120(8), 899903.
  • 57
    Roy, R., Maraveyas, A. (2010) Chemoradiation in pancreatic adenocarcinoma: a literature review. Oncologist, 15(3), 259269.
  • 58
    Neoptolemos, J.P., Dunn, J.A., Stocken, D.D., Almond, J., Link, K., Beger, H. (2001) Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet, 358(9293), 15761585.
  • 59
    Neoptolemos, J.P., Stocken, D.D., Friess, H., Bassi, C., Dunn, J.A., Hickey, H. (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med, 350(12), 12001210.
  • 60
    Neoptolemos, J.P., Stocken, D.D., Bassi, C., Ghaneh, P., Cunningham, D., Goldstein, D. (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA, 304(10), 10731081.
  • 61
    Regine, W.F., Winter, K.A., Abrams, R.A., Safran, H., Hoffman, J.P., Konski, A. (2008) Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA, 299(9), 10191026.
  • 62
    Moertel, C.G., Frytak, S., Hahn, R.G., O’Connell, M.J., Reitemeier, R.J., Rubin, J. (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads +5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer, 48(8), 17051710.
  • 63
    Minsky, B.D., Hilaris, B., Fuks, Z. (1988) The role of radiation therapy in the control of pain from pancreatic carcinoma. J Pain Symptom Manage, 3(4), 199205.
  • 64
    Chauffert, B., Mornex, F., Bonnetain, F., Rougier, P., Mariette, C., Bouche, O. (2008) Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol, 19(9), 15921599.
  • 65
    Ohhashi, K., Murakami, Y., Takekoshi, T. (1982) Four cases of mucin producing cancer of pancreas on specific findings of the papilla of Vater. Prog Dig Endosc, 20, 348351.
  • 66
    Longnecker, D.S., Hruban, R.H. (2000) Intraductal papillary-mucinous neoplasms of the pancreas. In: S.R. Hamilton, A.L., (ed), WHO Classification of Tumors Pathology and Genetics of Tumours of Digestive System, pp. 237240. IARC Press, Lyon.
  • 67
    Jang, J.Y., Kim, S.W., Ahn, Y.J., Yoon, Y.S., Choi, M.G., Lee, K.U. (2005) Multicenter analysis of clinicopathologic features of intraductal papillary mucinous tumor of the pancreas: is it possible to predict the malignancy before surgery? Ann Surg Oncol, 12(2), 124132.
  • 68
    Sarr, M.G., Kendrick, M.L., Nagorney, D.M., Thompson, G.B., Farley, D.R., Farnell, M.B. (2001) Cystic neoplasms of the pancreas: benign to malignant epithelial neoplasms. Surg Clin North Am, 81(3), 497509.
  • 69
    Obara, T., Maguchi, H., Saitoh, Y., Itoh, A., Arisato, S., Ashida, T. (1993) Mucin-producing tumor of the pancreas: natural history and serial pancreatogram changes. Am J Gastroenterol, 88(4), 564569.
  • 70
    Tanaka, M., Kobayashi, K., Mizumoto, K., Yamaguchi, K. (2005) Clinical aspects of intraductal papillary mucinous neoplasm of the pancreas. J Gastroenterol, 40(7), 669675.
  • 71
    Morana, G., Guarise, A. (2006) Cystic tumors of the pancreas. Cancer Imaging, 6, 6071.
  • 72
    Sohn, T.A., Yeo, C.J., Cameron, J.L., Hruban, R.H., Fukushima, N., Campbell, K.A. (2004) Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg, 239(6), 788797; discussion 97–99.
  • 73
    Tanaka, M., Chari, S., Adsay, V., Fernandez-del Castillo, C., Falconi, M., Shimizu, M. (2006) International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology, 6(1–2), 1732.
  • 74
    Fujino, Y., Suzuki, Y., Yoshikawa, T., Ajiki, T., Ueda, T., Matsumoto, I. (2006) Outcomes of surgery for intraductal papillary mucinous neoplasms of the pancreas. World J Surg, 30(10), 19091914; discussion 15.
  • 75
    Salvia, R., Crippa, S., Falconi, M., Bassi, C., Guarise, A., Scarpa, A. (2007) Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate? Gut, 56(8), 10861090.
  • 76
    Wada, K., Kozarek, R.A., Traverso, L.W. (2005) Outcomes following resection of invasive and noninvasive intraductal papillary mucinous neoplasms of the pancreas. Am J Surg, 189(5), 632636; discussion 7.
  • 77
    D'Angelica, M., Brennan, M.F., Suriawinata, A.A., Klimstra, D., Conlon, K.C. (2004) Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg, 239(3), 400408.
  • 78
    Eloubeidi, M.A., Hawes, R.H. (2000) Mucinous tumors of the exocrine pancreas. Cancer Control, 7(5), 445451.
  • 79
    Zamboni, G., Scarpa, A., Bogina, G., Iacono, C., Bassi, C., Talamini, G. (1999) Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. Am J Surg Pathol, 23(4), 410422.
  • 80
    Thompson, L.D., Becker, R.C., Przygodzki, R.M., Adair, C.F., Heffess, C.S. (1999) Mucinous cystic neoplasm (mucinous cystadenocarcinoma of low-grade malignant potential) of the pancreas: a clinicopathologic study of 130 cases. Am J Surg Pathol, 23(1), 116.
  • 81
    Procacci, C., Biasiutti, C., Carbognin, G., Accordini, S., Bicego, E., Guarise, A. (1999) Characterization of cystic tumors of the pancreas: CT accuracy. J Comput Assist Tomogr, 23(6), 906912.
  • 82
    Halfdanarson, T.R., Rubin, J., Farnell, M.B., Grant, C.S., Petersen, G.M. (2008) Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer, 15(2), 409427.
  • 83
    Kimura, W., Kuroda, A., Morioka, Y. (1991) Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig Dis Sci, 36(7), 933942.
  • 84
    Debas, H.T., Mulvihill, S.J. (1994) Neuroendocrine gut neoplasms. Important lessons from uncommon tumors. Arch Surg, 129(9), 965971; discussion 71–72.
  • 85
    Tomassetti, P., Migliori, M., Lalli, S., Campana, D., Tomassetti, V., Corinaldesi, R. (2001) Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours. Ann Oncol, 12(Suppl 2), S95–S99.
  • 86
    Yubin, L., Chihua, F., Zhixiang, J., Jinrui, O., Zixian, L., Jianghua, Z. (2008) Surgical management and prognostic factors of hilar cholangiocarcinoma: experience with 115 cases in China. Ann Surg Oncol, 15(8), 21132119.
  • 87
    Abbas, G., Lindor, K.D. (2009) Cholangiocarcinoma in primary sclerosing cholangitis. J Gastrointest Cancer, 40(1–2), 1925.
  • 88
    Gatto, M., Bragazzi, M.C., Semeraro, R., Napoli, C., Gentile, R., Torrice, A. (2010) Cholangiocarcinoma: update and future perspectives. Dig Liver Dis, 42(4), 253260.
  • 89
    Welzel, T.M., McGlynn, K.A., Hsing, A.W., O'Brien, T.R., Pfeiffer, R.M. (2006) Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst, 98(12), 873875.
  • 90
    Klatskin, G. (1965) Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. An unusual tumor with distinctive clinical and pathological features. Am J Med, 38, 241256.
  • 91
    Maithel, S.K., Jarnagin, W.R. (2010) Malignant lesions of the biliary tract. In: O.J. Garden (ed), Hepatobiliary and Pancreatic Surgery, pp. 219242. Elsevier.
  • 92
    Weinbren, K., Mutum, S.S. (1983) Pathological aspects of cholangiocarcinoma. J Pathol, 139(2), 217238.
  • 93
    Yamamoto, J., Kosuge, T., Shimada, K., Takayama, T., Yamasaki, S., Ozaki, H. (1993) Intrahepatic cholangiocarcinoma: proposal of new macroscopic classification. Nippon Geka Gakkai Zasshi, 94(11), 11941200.
  • 94
    Pitt, H.A., Dooley, W.C., Yeo, C.J., Cameron, J.L. (1995) Malignancies of the biliary tree. Curr Probl Surg, 32(1), 190.
  • 95
    Bergquist, A., Ekbom, A., Olsson, R., Kornfeldt, D., Loof, L., Danielsson, A. (2002) Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol, 36(3), 321327.
  • 96
    Burak, K., Angulo, P., Pasha, T.M., Egan, K., Petz, J., Lindor, K.D. (2004) Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol, 99(3), 523526.
    Direct Link:
  • 97
    Khan, S.A., Thomas, H.C., Davidson, B.R., Taylor-Robinson, S.D. (2005) Cholangiocarcinoma. Lancet, 366(9493), 13031314.
  • 98
    Boberg, K.M., Bergquist, A., Mitchell, S., Pares, A., Rosina, F., Broome, U. (2002) Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol, 37(10), 12051211.
  • 99
    Charatcharoenwitthaya, P., Enders, F.B., Halling, K.C., Lindor, K.D. (2008) Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology, 48(4), 11061117.
  • 100
    Levy, C., Lymp, J., Angulo, P., Gores, G.J., Larusso, N., Lindor, K.D. (2005) The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci, 50(9), 17341740.
  • 101
    Abdalla, E.K., Forsmark, C.E., Lauwers, G.Y., Vauthey, J.N. (1999) Monolobar Caroli's disease and cholangiocarcinoma. HPB Surg, 11(4), 271276; discussion 6–7.
  • 102
    de Vries, J.S., de Vries, S., Aronson, D.C., Bosman, D.K., Rauws, E.A., Bosma, A. (2002) Choledochal cysts: age of presentation, symptoms, and late complications related to Todani's classification. J Pediatr Surg, 37(11), 15681573.
  • 103
    Voyles, C.R., Smadja, C., Shands, W.C., Blumgart, L.H. (1983) Carcinoma in choledochal cysts. Age-related incidence. Arch Surg, 118(8), 986988.
  • 104
    Miyazaki, M., Takada, T., Miyakawa, S., Tsukada, K., Nagino, M., Kondo, S. (2008) Risk factors for biliary tract and ampullary carcinomas and prophylactic surgery for these factors. J Hepatobiliary Pancreat Surg, 15(1), 1524.
  • 105
    Tashiro, S., Imaizumi, T., Ohkawa, H., Okada, A., Katoh, T., Kawaharada, Y. (2003) Pancreaticobiliary maljunction: retrospective and nationwide survey in Japan. J Hepatobiliary Pancreat Surg, 10(5), 345351.
  • 106
    Su, C.H., Shyr, Y.M., Lui, W.Y., P'Eng, F.K. (1997) Hepatolithiasis associated with cholangiocarcinoma. Br J Surg, 84(7), 969973.
  • 107
    Rizzi, P.M., Ryder, S.D., Portmann, B., Ramage, J.K., Naoumov, N.V., Williams, R. (1996) p53 Protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis. Gut, 38(2), 265268.
  • 108
    Sturm, P.D., Baas, I.O., Clement, M.J., Nakeeb, A., Johan, G., Offerhaus, A. (1998) Alterations of the p53 tumor-suppressor gene and K-ras oncogene in perihilar cholangiocarcinomas from a high-incidence area. Int J Cancer, 78(6), 695698.
  • 109
    Wattanasirichaigoon, S., Tasanakhajorn, U., Jesadapatarakul, S. (1998) The incidence of K-ras codon 12 mutations in cholangiocarcinoma detected by polymerase chain reaction technique. J Med Assoc Thai, 81(5), 316323.
  • 110
    Terada, T., Ashida, K., Endo, K., Horie, S., Maeta, H., Matsunaga, Y. (1998) c-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma. Histopathology, 33(4), 325331.
  • 111
    Vatanasapt, V., Tangvoraphonkchai, V., Titapant, V., Pipitgool, V., Viriyapap, D., Sriamporn, S. (1990) A high incidence of liver cancer in Khon Kaen Province, Thailand. Southeast Asian J Trop Med Public Health, 21(3), 489494.
  • 112
    Shin, H.R., Lee, C.U., Park, H.J., Seol, S.Y., Chung, J.M., Choi, H.C. (1996) Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. Int J Epidemiol, 25(5), 933940.
  • 113
    Zhou, Y.M., Yin, Z.F., Yang, J.M., Li, B., Shao, W.Y., Xu, F. (2008) Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China. World J Gastroenterol, 14(4), 632635.
  • 114
    El-Serag, H.B., Engels, E.A., Landgren, O., Chiao, E., Henderson, L., Amaratunge, H.C. (2009) Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans. Hepatology, 49(1), 116123.
  • 115
    Lipshutz, G.S., Brennan, T.V., Warren, R.S. (2002) Thorotrast-induced liver neoplasia: a collective review. J Am Coll Surg, 195(5), 713718.
  • 116
    Ito, Y., Kojiro, M., Nakashima, T., Mori, T. (1988) Pathomorphologic characteristics of 102 cases of thorotrast-related hepatocellular carcinoma, cholangiocarcinoma, and hepatic angiosarcoma. Cancer, 62(6), 11531162.
  • 117
    Khan, S.A., Davidson, B.R., Goldin, R., Pereira, S.P., Rosenberg, W.M., Taylor-Robinson, S.D. (2002) Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut, 51(Suppl 6), VI1–VI19.
  • 118
    Patel, A.H., Harnois, D.M., Klee, G.G., LaRusso, N.F., Gores, G.J. (2000) The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol, 95(1), 204207.
    Direct Link:
  • 119
    Sakamoto, E., Nimura, Y., Hayakawa, N., Kamiya, J., Kondo, S., Nagino, M. (1998) The pattern of infiltration at the proximal border of hilar bile duct carcinoma: a histologic analysis of 62 resected cases. Ann Surg, 227(3), 405411.
  • 120
    Ebata, T., Watanabe, H., Ajioka, Y., Oda, K., Nimura, Y. (2002) Pathological appraisal of lines of resection for bile duct carcinoma. Br J Surg, 89(10), 12601267.
  • 121
    Sharma, M.P., Ahuja, V. (1999) Aetiological spectrum of obstructive jaundice and diagnostic ability of ultrasonography: a clinician's perspective. Trop Gastroenterol, 20(4), 167169.
  • 122
    Cho, E.S., Park, M.S., Yu, J.S., Kim, M.J., Kim, K.W. (2007) Biliary ductal involvement of hilar cholangiocarcinoma: multidetector computed tomography versus magnetic resonance cholangiography. J Comput Assist Tomogr, 31(1), 7278.
  • 123
    Lee, S.S., Kim, M.H., Lee, S.K., Kim, T.K., Seo, D.W., Park, J.S. (2002) MR cholangiography versus cholangioscopy for evaluation of longitudinal extension of hilar cholangiocarcinoma. Gastrointest Endosc, 56(1), 2532.
  • 124
    Manfredi, R., Barbaro, B., Masselli, G., Vecchioli, A., Marano, P. (2004) Magnetic resonance imaging of cholangiocarcinoma. Semin Liver Dis, 24(2), 155164.
  • 125
    Manfredi, R., Masselli, G., Maresca, G., Brizi, M.G., Vecchioli, A., Marano, P. (2003) MR imaging and MRCP of hilar cholangiocarcinoma. Abdom Imaging, 28(3), 319325.
  • 126
    Choi, J.Y., Kim, M.J., Lee, J.M., Kim, K.W., Lee, J.Y., Han, J.K. (2008) Hilar cholangiocarcinoma: role of preoperative imaging with sonography, MDCT, MRI, and direct cholangiography. AJR Am J Roentgenol, 191(5), 14481457.
  • 127
    Freeman, M.L. (2002) Adverse outcomes of ERCP. Gastrointest Endosc, 56(6, Suppl), S273–S282.
  • 128
    Chung, Y.E., Kim, M.J., Park, Y.N., Choi, J.Y., Pyo, J.Y., Kim, Y.C. (2009) Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. Radiographics, 29(3), 683700.
  • 129
    Buc, E., Lesurtel, M., Belghiti, J. (2008) Is preoperative histological diagnosis necessary before referral to major surgery for cholangiocarcinoma? HPB (Oxford), 10(2), 98105.
  • 130
    Bismuth, H., Nakache, R., Diamond, T. (1992) Management strategies in resection for hilar cholangiocarcinoma. Ann Surg, 215(1), 3138.
  • 131
    Sobin, L., Gospodarowicz, M., Wittekind, C (eds). (2010) TNM Classification of Malignant Tumours, 7th ed. Blackwell Publishing, Oxford.
  • 132
    Jarnagin, W.R., Fong, Y., DeMatteo, R.P., Gonen, M., Burke, E.C., Bodniewicz, B.J. (2001) Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg, 234(4), 507517; discussion 17–19.
  • 133
    Ohtsuka, M., Ito, H., Kimura, F., Shimizu, H., Togawa, A., Yoshidome, H. (2002) Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg, 89(12), 15251531.
  • 134
    Isaji, S., Kawarada, Y., Taoka, H., Tabata, M., Suzuki, H., Yokoi, H. (1999) Clinicopathological features and outcome of hepatic resection for intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreat Surg, 6(2), 108116.
  • 135
    Valverde, A., Bonhomme, N., Farges, O., Sauvanet, A., Flejou, J.F., Belghiti, J. (1999) Resection of intrahepatic cholangiocarcinoma: a Western experience. J Hepatobiliary Pancreat Surg, 6(2), 122–127.
  • 136
    Hasegawa, S., Ikai, I., Fujii, H., Hatano, E., Shimahara, Y. (2007) Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J Surg, 31(6), 12561263.
  • 137
    DeOliveira, M.L., Cunningham, S.C., Cameron, J.L., Kamangar, F., Winter, J.M., Lillemoe, K.D. (2007) Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg, 245(5), 755762.
  • 138
    Fong, Y., Blumgart, L.H., Lin, E., Fortner, J.G., Brennan, M.F. (1996) Outcome of treatment for distal bile duct cancer. Br J Surg, 83(12), 17121715.
  • 139
    Wade, T.P., Prasad, C.N., Virgo, K.S., Johnson, F.E. (1997) Experience with distal bile duct cancers in U.S. Veterans Affairs hospitals: 1987-1991. J Surg Oncol, 64(3), 242245.
  • 140
    Weber, S.M., DeMatteo, R.P., Fong, Y., Blumgart, L.H., Jarnagin, W.R. (2002) Staging laparoscopy in patients with extrahepatic biliary carcinoma. Analysis of 100 patients. Ann Surg, 235(3), 392399.
  • 141
    Kiesslich, T., Wolkersdorfer, G., Neureiter, D., Salmhofer, H., Berr, F. (2009) Photodynamic therapy for non-resectable perihilar cholangiocarcinoma. Photochem Photobiol Sci, 8(1), 2330.
  • 142
    Baisden, J.M., Kahaleh, M., Weiss, G.R., Sanfey, H., Moskaluk, C.A., Yeaton, P. (2008) Multimodality treatment with helical tomotherapy intensity modulated radiotherapy, capecitabine, and photodynamic therapy is feasible and well tolerated in patients with hilar cholangiocarcinoma. Gastrointest Cancer Res, 2(5), 219224.
  • 143
    Kuvshinoff, B.W., Armstrong, J.G., Fong, Y., Schupak, K., Getradjman, G., Heffernan, N. (1995) Palliation of irresectable hilar cholangiocarcinoma with biliary drainage and radiotherapy. Br J Surg, 82(11), 15221525.
  • 144
    Lazcano-Ponce, E.C., Miquel, J.F., Munoz, N., Herrero, R., Ferrecio, C., Wistuba, I.I. (2001) Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin, 51(6), 349364.
  • 145
    Albores-Saavedra, J., de Jesus Manrique, J., Angeles-Angeles, A., Henson, D.E. (1984) Carcinoma in situ of the gallbladder. A clinicopathologic study of 18 cases. Am J Surg Pathol, 8(5), 323333.
  • 146
    Henson, D.E., Albores-Saavedra, J., Corle, D. (1992) Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates. Cancer, 70(6), 14931497.
  • 147
    Strom, B.L., Soloway, R.D., Rios-Dalenz, J.L., Rodriguez-Martinez, H.A., West, S.L., Kinman, J.L. (1995) Risk factors for gallbladder cancer. An international collaborative case-control study. Cancer, 76(10), 17471756.
  • 148
    Okamoto, M., Okamoto, H., Kitahara, F., Kobayashi, K., Karikome, K., Miura, K. (1999) Ultrasonographic evidence of association of polyps and stones with gallbladder cancer. Am J Gastroenterol, 94(2), 446450.
  • 149
    Yeh, C.N., Jan, Y.Y., Chao, T.C., Chen, M.F. (2001) Laparoscopic cholecystectomy for polypoid lesions of the gallbladder: a clinicopathologic study. Surg Laparosc Endosc Percutan Tech, 11(3), 176181.
  • 150
    Stephen, A.E., Berger, D.L. (2001) Carcinoma in the porcelain gallbladder: a relationship revisited. Surgery, 129(6), 699703.
  • 151
    Caygill, C.P., Hill, M.J., Braddick, M., Sharp, J.C. (1994) Cancer mortality in chronic typhoid and paratyphoid carriers. Lancet, 343(8889), 8384.
  • 152
    Bartlett, D.L., Fong, Y., Fortner, J.G., Brennan, M.F., Blumgart, L.H. (1996) Long-term results after resection for gallbladder cancer. Implications for staging and management. Ann Surg, 224(5), 639646.
  • 153
    Kalra, N., Suri, S., Gupta, R., Natarajan, S.K., Khandelwal, N., Wig, J.D. (2006) MDCT in the staging of gallbladder carcinoma. AJR Am J Roentgenol, 186(3), 758762.
  • 154
    Jang, J.Y., Kim, S.W., Lee, S.E., Hwang, D.W., Kim, E.J., Lee, J.Y. (2009) Differential diagnostic and staging accuracies of high resolution ultrasonography, endoscopic ultrasonography, and multidetector computed tomography for gallbladder polypoid lesions and gallbladder cancer. Ann Surg, 250(6), 943949.
  • 155
    Shirai, Y., Yoshida, K., Tsukada, K., Muto, T. (1992) Inapparent carcinoma of the gallbladder. An appraisal of a radical second operation after simple cholecystectomy. Ann Surg, 215(4), 326331.
  • 156
    de Aretxabala, X.A., Roa, I.S., Burgos, L.A., Araya, J.C., Villaseca, M.A., Silva, J.A. (1997) Curative resection in potentially resectable tumours of the gallbladder. Eur J Surg, 163(6), 419426.
  • 157
    Chijiiwa, K., Tanaka, M. (1994) Carcinoma of the gallbladder: an appraisal of surgical resection. Surgery, 115(6), 751756.
  • 158
    Rajagopalan, V, Daines, W.P., Grossbard, M.L., Kozuch, P. (2004) Gallbladder and biliary tract carcinoma: a comprehensive update, Part 1. Oncology (Williston Park), 18(7), 889896.
  • 159
    Daines, W.P., Rajagopalan, V, Grossbard, M.L., Kozuch, P. (2004) Gallbladder and biliary tract carcinoma: a comprehensive update, Part 2. Oncology (Williston Park), 18(8), 10491059; discussion 60, 65–66, 68.